AllRock Bio $50M Series A: Pipeline Trigger
AllRock Bio just raised $50M to fuel ROC-101 Phase 2. Target Catherine Pearce with clinical ops and regulatory platforms to fill your pipeline and seal the deal.
Published on
Do not index
Do not index
🚀 Battle Card: AllRock Bio
Quick trigger:
👤 Decision Maker in the News
- Catherine Pearce, DHSc, MBA, Co-Founder & CEO 📧 cpearce@allrockbio.com
💡 Why It Matters
- This AllRock Bio sales trigger brings fresh funding to support ROC-101’s Phase 2 launch → Source
🎯 Core Pain Point
- Advancing ROC-101 efficiently into Phase 2 trials
- Scaling clinical operations under tight timelines
💰 What to Pitch
- Primary: Clinical Trial Management Solutions → Streamline Phase 2 workflows
- Expansion: Regulatory Affairs Platforms → Accelerate FDA submissions
🗺️ Quick Context
- HQ: Natick, MA
- Employees: ≈ 75
- Rev: ≈ $0
- Website: allrockbio.com
🤼 Competitive Intel
*Which other vendors you’ll probably face to win AllRock Bio’s business.*
- United Therapeutics — PAH therapies
- Unique edge: Market leader for PAH drugs
- Evaluated by Clinical Ops & CMO
- Actelion (Janssen) — PAH & fibrosis pipeline
- Unique edge: Deep pipeline and M&A support
- Evaluated by CEO’s strategic R&D team
- Bayer — Fibrosis therapeutics
- Unique edge: Global distribution network
- Evaluated by COO for scale
- FibroGen — Anti-fibrotic drugs
- Unique edge: Phase 3 programs nearing readout
- Evaluated by Clinical Ops for comparator data
✅ Do-Now Checklist
Reference the AllRock Bio sales trigger in your first email subject
Leverage the AllRock Bio sales trigger insights to tailor solutions
Tailor outreach around their Phase 2 push and regulatory needs
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑NewsletterForLeads❑
OFFER_BRIEF = ❑Streamlined clinical trial workflows❑
PROOF_METRIC = ❑50% faster phase transitions❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Catherine
COMPANY = AllRock Bio
DEPT = Clinical Operations
SIZE = 75
BOTTLENECK = Scaling clinical ops under tight timelines
EVENT = Series A funding
DETAIL = AllRock Bio Announces $50M Series A Round
PAIN = Advancing ROC-101 efficiently into Phase 2 trials
SRC = https://vcnewsdaily.com/allrock-bio/venture-capital-funding/kzdwhxzvgl
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = TBD
EMP_EST = 75
REV_EST = ≈ $0M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 75-person Clinical Operations
Catherine—noticed your Clinical Operations team is ≈ 75.
That’s when Scaling clinical ops under tight timelines slows growth.
We helped ≈ TBD fix this with Streamlined clinical trial workflows.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about AllRock Bio Announces $50M Series A Round — Advancing ROC-101 efficiently into Phase 2 trials.
Streamlined clinical trial workflows. 50% faster phase transitions.
Quick chat?